Int J Stem Cells. 2016 May 30;9(1):53-9. doi: 10.15283/ijsc.2016.9.1.53.

Genetically Engineered In Vitro Erythropoiesis.

International journal of stem cells

Cristopher Geiler, Inez Andrade, Alexandra Clayton, Daniel Greenwald

PMID: 27426086 PMCID: PMC4961104 DOI: 10.15283/ijsc.2016.9.1.53

Abstract

BACKGROUND: Engineered blood has the greatest potential to combat a predicted future shortfall in the US blood supply for transfusion treatments. Engineered blood produced from hematopoietic stem cell (HSC) derived red blood cells in a laboratory is possible, but critical barriers exist to the production of clinically relevant quantities of red blood cells required to create a unit of blood. Erythroblasts have a finite expansion capacity and there are many negative regulatory mechanisms that inhibit in vitro erythropoiesis. In order to overcome these barriers and enable mass production, the expansion capacity of erythroblasts in culture will need to be exponentially improved over the current state of art. This work focused on the hypothesis that genetic engineering of HSC derived erythroblasts can overcome these obstacles.

OBJECTIVES: The objective of this research effort was to improve in vitro erythropoiesis efficiency from human adult stem cell derived erythroblasts utilizing genetic engineering. The ultimate goal is to enable the mass production of engineered blood.

METHODS: HSCs were isolated from blood samples and cultured in a liquid media containing growth factors. Cells were transfected using a Piggybac plasmid transposon.

RESULTS: Cells transfected with SPI-1 continued to proliferate in a liquid culture media. Fluorescence-activated cell sorting (FACS) analysis on culture day 45 revealed a single population of CD71⁺CD117⁺ proerythroblast cells. The results of this study suggest that genetically modified erythroblasts could be immortalized in vitro by way of a system modeling murine erythroleukemia.

CONCLUSION: Genetic modification can increase erythroblast expansion capacity and potentially enable mass production of red blood cells.

Keywords: Adult Stem Cells; Erythroblasts; Erythroleukemia; Erythropoiesis; Hematopoietic Stem Cells

References

1. Blood. 2004 Dec 1;104(12):3437-44 - PubMed
2. Blood. 2005 Sep 15;106(6):2162-8 - PubMed
3. J Cell Mol Med. 2009 Nov-Dec;13(11-12):4349-63 - PubMed
4. Int J Hematol. 2008 May;87(4):339-50 - PubMed
5. Leuk Res. 2004 Jan;28(1):83-9 - PubMed
6. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547-51 - PubMed
7. Nat Biotechnol. 2006 Oct;24(10):1255-6 - PubMed
8. Blood. 2001 May 15;97(10):3075-85 - PubMed
9. Blood. 2011 Nov 10;118(19):5071-9 - PubMed
10. Leukemia. 2010 Jul;24(7):1249-57 - PubMed
11. Anaesthesia. 2012 May;67(5):493-500 - PubMed
12. Transfusion. 2011 Apr;51(4):670-3 - PubMed
13. Int J Stem Cells. 2014 Nov;7(2):153-7 - PubMed
14. Blood. 2005 Jan 1;105(1):85-94 - PubMed
15. Methods. 2011 Apr;53(4):366-71 - PubMed
16. Oncogene. 1998 Jun 11;16(23):2989-95 - PubMed
17. Transfusion. 2005 Feb;45(2):141-8 - PubMed
18. Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9290-5 - PubMed
19. Blood. 2000 Jun 15;95(12):3716-24 - PubMed
20. Transfusion. 1995 Oct;35(10):802-12 - PubMed
21. J Exp Med. 1978 Feb 1;147(2):324-39 - PubMed
22. Proc Natl Acad Sci U S A. 1971 Jul;68(7):1542-6 - PubMed
23. Transfusion. 1993 Feb;33(2):139-44 - PubMed
24. IUBMB Life. 2010 Jul;62(7):492-6 - PubMed
25. Int J Biochem Cell Biol. 1999 Oct;31(10):1089-109 - PubMed
26. N Engl J Med. 1990 Jun 7;322(23):1646-51 - PubMed
27. Transfusion. 2002 Oct;42(10):1253-60 - PubMed
28. Trends Cell Biol. 2005 Mar;15(3):146-55 - PubMed
29. Blood. 2011 Jun 9;117(23):6083-90 - PubMed
30. Exp Hematol. 2005 Jul;33(7):828-35 - PubMed
31. Leuk Lymphoma. 2013 Nov;54(11):2523-30 - PubMed
32. PLoS One. 2011;6(7):e22148 - PubMed
33. Blood Cells Mol Dis. 2002 Mar-Apr;28(2):169-80 - PubMed
34. Mol Cell Biol. 1996 May;16(5):2453-63 - PubMed

Publication Types

• Journal Article